Disease Modifying Monoclonal Antibodies and Symptomatic Pharmacological Treatment for Alzheimer’s Disease

Biomedicines, Год журнала: 2024, Номер 12(11), С. 2636 - 2636

Опубликована: Ноя. 19, 2024

Alzheimer's Disease (AD) is an irreversible, progressive syndrome characterized by neurocognitive impairment. Two neuropathological features seen in AD are extracellular amyloid plaques consisting of beta1-40 and 1-42, intracellular neurofibrillary tangles (NFTs). For decades, neuroscience research has heavily focused on seeking to understand the primary mechanism searching for pharmacological approaches treatment dementia. Three monoclonal antibodies that act against beta-aducanumab, lecanemab, donanemab-have been approved Food Drug Administration (FDA) mild cognitive impairment AD, addition medications symptom management such as acetylcholinesterase inhibitors N-methyl-D-aspartate (NMDA) antagonist. Further trials should focus combination therapies targeting tau pathology.

Язык: Английский

Echoes in the night: How sleep quality influences auditory health

Neuroscience, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Язык: Английский